Panipenem

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 461483

CAS#: 87726-17-8

Description: Panipenem is a carbapenem antibiotic used in combination with betamipron.

Chemical Structure

img
Panipenem
CAS# 87726-17-8
Instruction

Theoretical Analysis

MedKoo Cat#: 461483
Name: Panipenem
CAS#: 87726-17-8
Chemical Formula: C15H21N3O4S
Exact Mass: 339.13
Molecular Weight: 339.410
Elemental Analysis: C, 53.08; H, 6.24; N, 12.38; O, 18.86; S, 9.45

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Panipenem; CS 533; CS-533; CS533; RS 533; RS-533; RS533;

IUPAC/Chemical Name: (5R,6S)-6-((R)-1-hydroxyethyl)-3-(((S)-1-(1-iminoethyl)pyrrolidin-3-yl)thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

InChi Key: TYMABNNERDVXID-DLYFRVTGSA-N

InChi Code: InChI=1S/C15H21N3O4S/c1-7(19)12-10-5-11(13(15(21)22)18(10)14(12)20)23-9-3-4-17(6-9)8(2)16/h7,9-10,12,16,19H,3-6H2,1-2H3,(H,21,22)/t7-,9+,10-,12-/m1/s1

SMILES Code: O=C(C(N12)=C(S[C@@H]3CN(C(C)=N)CC3)C[C@]2([H])[C@@H]([C@H](O)C)C1=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 339.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kato A, Ueyama J, Abe F, Hotta K, Tsukiyama I, Oshima T, Kondo F, Saito H, Hasegawa T. Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats. Anticancer Res. 2011 Sep;31(9):2915-22. PubMed PMID: 21868538.

2: Nakagawa Y, Suzuki K, Ohta K, Hino M, Ohyashiki K, Kanamaru A, Tamura K, Urabe A, Masaoka T; Japan Febrile Neutropenia Study Group. Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neutropenia. J Infect Chemother. 2013 Feb;19(1):103-11. doi: 10.1007/s10156-012-0466-8. Epub 2012 Sep 5. PubMed PMID: 22948387.

3: Suzuki H, Tokuda Y, Shichi D, Hitomi S, Ishikawa H, Maeno T, Nakamura H. A retrospective cohort study of panipenem/betamipron for adult pneumococcal bacteremia at three teaching hospitals in Japan. J Infect Chemother. 2013 Aug;19(4):607-14. doi: 10.1007/s10156-012-0525-1. Epub 2012 Dec 1. PubMed PMID: 23203218.

4: Ji J, Du X, Chen Y, Fu Y, Wang H, Yu Y. In vitro activity of sulbactam in combination with imipenem, meropenem, panipenem or cefoperazone against clinical isolates of Acinetobacter baumannii. Int J Antimicrob Agents. 2013 Apr;41(4):400-1. doi: 10.1016/j.ijantimicag.2012.12.014. Epub 2013 Feb 12. PubMed PMID: 23410789.

5: Clinical Trial Research Group on Panipenem-betamipron. [The clinical efficacy and safety of panipenem-betamipron in treatment of moderate to severe pulmonary infection]. Zhonghua Nei Ke Za Zhi. 2012 Jul;51(7):547-50. Chinese. PubMed PMID: 22943829.

6: Goa KL, Noble S. Panipenem/betamipron. Drugs. 2003;63(9):913-25; discussion 926. Review. PubMed PMID: 12678575.

7: Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother. 2004 Apr;48(4):1159-67. PubMed PMID: 15047516; PubMed Central PMCID: PMC375245.

8: Ohashi N, Uematsu T, Nagashima S, Kanamaru M, Tajima N, Togawa A, Hishida A. Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease. J Infect Chemother. 2005 Feb;11(1):24-31. PubMed PMID: 15729484.

9: Kwon KT, Cheong HS, Rhee JY, Wi YM, Ryu SY, Heo ST, Moon CS, Ki HK, Kim KH, Jung CW, Peck KR, Song JH. Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial. Jpn J Clin Oncol. 2008 Jan;38(1):49-55. doi: 10.1093/jjco/hym151. Epub 2008 Jan 17. PubMed PMID: 18203711.

10: Kojima S, Nadai M, Kitaichi K, Wang L, Nabeshima T, Hasegawa T. Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats. Antimicrob Agents Chemother. 1998 Dec;42(12):3136-40. PubMed PMID: 9835504; PubMed Central PMCID: PMC106012.

11: Tajima N, Ishizuka H, Naganuma H. Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function. Chemotherapy. 2006;52(5):245-53. Epub 2006 Jul 25. PubMed PMID: 16864999.

12: Li JJ, Jia YQ, Cui X, Huang J, He C. [Preliminary clinical evaluations of panipenem-betamipron in the treatment of hematological malignancy infections]. Zhonghua Yi Xue Za Zhi. 2012 Feb 21;92(7):452-5. doi: 10.3760/cma.j.issn.00376-2491-2012.07.006. Chinese. PubMed PMID: 22490964.

13: Ito N, Suzuki M, Kusai A, Takayama K. Effect of initial concentration on stability of panipenem in aqueous solution. Chem Pharm Bull (Tokyo). 2005 Mar;53(3):323-7. PubMed PMID: 15744107.

14: Fukuoka T, Ohya S, Narita T, Katsuta M, Iijima M, Masuda N, Yasuda H, Trias J, Nikaido H. Activity of the carbapenem panipenem and role of the OprD (D2) protein in its diffusion through the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother. 1993 Feb;37(2):322-7. PubMed PMID: 8452364; PubMed Central PMCID: PMC187661.

15: Kaku M. [Adequate use of parenteral antibacterial agents: panipenem/betamipron (discussion)]. Jpn J Antibiot. 2012 Apr;65(2):99-110. Japanese. PubMed PMID: 22970633.

16: Kimura T, Kokubun H, Nowatari M, Matsuura N, Sunakawa K, Kubo H. Population pharmacokinetics of panipenem in neonates and retrospective evaluation of dosage. J Antimicrob Chemother. 2001 Jan;47(1):51-9. PubMed PMID: 11152431.

17: Kurihara A, Hisaoka M, Mikuni N, Kamoshida K. Neurotoxicity of panipenem/betamipron, a new carbapenem, in rabbits: correlation to concentration in central nervous system. J Pharmacobiodyn. 1992 Jul;15(7):325-32. PubMed PMID: 1447679.

18: Shimada J, Kawahara Y. Overview of a new carbapenem, panipenem/betamipron. Drugs Exp Clin Res. 1994;20(6):241-5. PubMed PMID: 7758396.

19: Tajima N, Soma M, Ishizuka H, Naganuma H. Quantitative evaluation of effect of renal failure on the pharmacokinetics of panipenem in rats. Biol Pharm Bull. 2005 Nov;28(11):2170-2. PubMed PMID: 16272714.

20: Hayakawa M, Ito Y, Fujita I, Iseki K, Gando S. Pharmacokinetics and the most suitable regimen of panipenem/beta mipron in critically ill patients receiving continuous renal replacement therapy: a pilot study. ASAIO J. 2006 Jul-Aug;52(4):398-403. PubMed PMID: 16883119.